The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Eli Lilly and Company (NYSE: LLY)今天宣布,其用于开始胰岛素治疗的2型糖尿病成年患者的每周一次胰岛素efsitora alfa ...

印第安纳波利斯 - Eli Lilly and Company (NYSE: LLY) 宣布美国食品药品监督管理局(FDA)批准其新型生物制剂EBGLYSS™ ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...